Open AccessHarnessing immunological targets for COVID-19 immunotherapy
Author(s) -
Abhishesh Kumar Mehata,
Matte Kasi Viswanadh,
Vishnu Priya,
. Vikas,
Madaswamy S. Muthu
Publication year - 2021
Publication title -
future virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.462
H-Index - 34
eISSN - 1746-0808
pISSN - 1746-0794
DOI - 10.2217/fvl-2021-0048
Subject(s) - immune system , innate immune system , immunity , immunology , immunotherapy , covid-19 , virology , biology , antibody , infectious disease (medical specialty) , disease , medicine , pathology
COVID-19 is an infectious and highly contagious disease caused by SARS-CoV-2. The immunotherapy strategy has a great potential to develop a permanent cure against COVID-19. Innate immune cells are in constant motion to scan molecular alteration to cells led by microbial infections throughout the body and helps in clearing invading viruses. Harnessing immunological targets for removing viral infection, generally based on the principle of enhancing the T-cell and protective immune responses. Currently-approved COVID-19 vaccines are mRNA encapsulated in liposomes that stimulate the host immune system to produce antibodies. Given the vital role of innate immunity, harnessing these immune responses opens up new hope for the generation of long-lasting and protective immunity against COVID-19.